Saturday, August 20, 2016 2:25:50 PM
MannKind Corp. (MNKD) Relaunches Groundbreaking Inhalable Insulin Afrezza®, Promotes New Copay System
MannKind Corp. (MNKD) Relaunches Groundbreaking Inhalable Insulin Afrezza®, Promotes New Copay System
Posted on August 19, 2016 by MissionIR
With over 29 million Americans living with diabetes, and more than 86 million with prediabetes, this disease is the seventh leading cause of death and swallows approximately 20% of nationwide healthcare spending, according to Centers for Disease Control and Prevention (CDC) statistics (http://nnw.fm/uUEx3). Healthcare officials, patients and doctors alike are always actively searching for new therapies or innovative yet affordable treatments to combat this disease.
This is where leading biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) and its groundbreaking inhalable insulin product Afrezza® come in. Touted as the first successful insulin inhaler on the U.S. market, Afrezza is a fast-acting inhalable insulin powder designed to be used in conjunction with regular type 1 and 2 diabetes treatments to help lower post-meal blood sugar spikes.
Beginning in July, MannKind relaunched Afrezza Inhalation Powder on the domestic market under its own branding, and the treatment is now available with major wholesalers, as well as by prescription in any retail pharmacy.
Leveraging its two-year experience in patient selection and copayment, the company has also announced several programs to promote patients’ access to Afrezza therapy. These include:
Enhanced copay assistance designed to lower insured patients’ out-of-pocket cost to $15 per month
Patient reimbursement support program, MannKind Cares
Bureau to educate and inform healthcare providers about the benefits of Afrezza
New titration pack that allows patients new to Afrezza more flexibility in adjusting their daily dosage
The new programs will join MannKind’s national salesforce, all of whom have extensive experience with diabetes and Afrezza, in its efforts to help enhance and streamline patients’ and providers’ experience with this key therapy. The company is committed to ensuring the treatment remains available to all diabetes patients in the U.S., without any disruption in supply.
The July relaunch came after the company released six more analyses of the pre-meal treatment, demonstrating a faster onset and shorter duration of action than with mealtime fast-acting insulin treatments. The findings, presented at the 76th scientific session of the American Diabetes Association, show that, compared to Eli Lilly and Company’s (NYSE: LLY) insulin lispro injection, Afrezza has a 50% faster onset and a 2-3-hour shorter duration of action.
The data supports the use of this therapy for rapidly controlling high glucose levels, according to the chief medical officer of MannKind, Raymond W. Urbanski, MD, PhD. Unlike injectable insulin, which risks causing hypoglycemia after a meal if dosed incorrectly, Afrezza works in the body more rapidly and leaves the bloodstream faster, offering an ideal balance between glucose control and a lower risk of hypoglycemia.
To find out more about MannKind Corp. and its innovative Afrezza Inhalation Powder insulin, visit www.MannkindCorp.com
Recent MNKD News
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease • GlobeNewswire Inc. • 09/18/2024 10:15:00 AM
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference • GlobeNewswire Inc. • 09/10/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:25:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 01:00:03 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 09:23:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/29/2024 08:15:28 PM
- MannKind to Present at Upcoming Conferences • GlobeNewswire Inc. • 08/27/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:03:59 PM
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 12:05:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 12:05:34 PM
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- US Index Futures Rise Amid Earnings Season Optimism, Oil Prices Rebound • IH Market News • 08/07/2024 09:49:12 AM
- MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease • GlobeNewswire Inc. • 07/31/2024 10:30:00 AM
- MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 • GlobeNewswire Inc. • 07/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 11:49:45 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM